VistaGen Therapeutics, Inc. - FORM S-1/A - EX-23.2 - CONSENT OF OUM & CO., LLP - May 5, 2016

Attached files

file filename
S-1/A - AMENDMENT NO. 2 TO FORM S-1 - VistaGen Therapeutics, Inc.vstas1a2_may52016.htm
EX-5.1 - OPINION OF DISCLOSURE LAW GROUP - VistaGen Therapeutics, Inc.ex5-1.htm
EX-1.1 - FORM OF WARRANT - VistaGen Therapeutics, Inc.ex1-1.htm
EX-4.10 - FORM OF WARRANT - VistaGen Therapeutics, Inc.ex4-10.htm
EX-4.11 - FORM OF WARRANT AGENCY AGREEMENT - VistaGen Therapeutics, Inc.ex4-11.htm

Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We hereby consent to the use, in the Prospectus constituting a part of this Amendment No. 2 to the Registration Statement on Form S-1 (No. 333-210152), of our report dated June 29, 2015 (which report expresses an unqualified opinion and includes an emphasis of matter paragraph concerning the ability of VistaGen Therapeutics, Inc. to continue as a going concern) relating to the consolidated financial statements of VistaGen Therapeutics, Inc., which is contained in that Prospectus.
 
We also consent to the reference to us under the caption “Experts” in the Prospectus.
 
/s/ OUM & CO. LLP
 
San Francisco, California
May 4, 2016

VistaGen Therapeutics, Inc. Reports

Also read